Symmetry Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Symmetry Partners, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 02, 2024	SELL	$902.69 - $993.35 $84,852 - $93,374	-94 Reduced 10.77%	779 $750,000
Q4 2023 Jan 02, 2024	SELL	$775.18 - $881.7 $240,305 - $273,327	-310 Reduced 26.2%	873 $770,000
Q3 2023 Oct 10, 2023	SELL	$692.45 - $844.37 $112,869 - $137,632	-163 Reduced 12.11%	1,183 $974,000
Q2 2023 Jul 05, 2023	SELL	$700.03 - $830.35 $282,112 - $334,631	-403 Reduced 23.04%	1,346 $967,000
Q1 2023 Apr 03, 2023	BUY	$680.49 - $826.97 $111,600 - $135,623	164 Added 10.35%	1,749 $1.44 Million
Q4 2022 Jan 06, 2023	SELL	$705.89 - $766.39 $55,765 - $60,544	-79 Reduced 4.75%	1,585 $1.14 Million
Q3 2022 Oct 03, 2022	BUY	$573.97 - $724.32 $76,911 - $97,058	134 Added 8.76%	1,664 $1.15 Million
Q2 2022 Jul 11, 2022	SELL	$548.35 - $738.84 $549,446 - $740,317	-1,002 Reduced 39.57%	1,530 $904,000
Q1 2022 Apr 04, 2022	BUY	$595.12 - $698.43 $974,211 - $1.14 Million	1,637 Added 182.91%	2,532 $1.77 Million
Q3 2021 Oct 18, 2021	BUY	$574.03 - $680.96 $45,922 - $54,476	80 Added 9.82%	895 $493,000
Q2 2021 Jul 07, 2021	BUY	$472.8 - $558.54 $104,961 - $123,995	222 Added 37.44%	815 $455,000
Q1 2021 May 03, 2021	SELL	$446.73 - $548.2 $240,787 - $295,479	-539 Reduced 47.61%	593 $281,000
Q4 2020 Feb 18, 2021	SELL	$478.3 - $607.98 $436,209 - $554,477	-912 Reduced 44.62%	1,132 $547,000
Q3 2020 Nov 03, 2020	BUY	$544.75 - $658.21 $489,185 - $591,072	898 Added 78.36%	2,044 $1.14 Million
Q2 2020 Jul 20, 2020	BUY	$493.32 - $643.92 $565,344 - $737,932	1,146 New	1,146 $715,000

1,480

85.7M

908K

1.3M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $90.4B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Symmetry Partners, LLC with notifications on news.